Biotechnology
Compare Stocks
5 / 10Stock Comparison
CDT vs DBVT vs ALKS vs CSWC vs ARCC
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Asset Management
Asset Management
CDT vs DBVT vs ALKS vs CSWC vs ARCC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Asset Management | Asset Management |
| Market Cap | $368K | $1712.35T | $5.90B | $1.43B | $13.61B |
| Revenue (TTM) | $696M | $0.00 | $1.56B | $164M | $3.15B |
| Net Income (TTM) | $17M | $-168M | $153M | $103M | $1.15B |
| Gross Margin | 36.9% | — | 65.4% | 66.5% | 75.7% |
| Operating Margin | 6.4% | — | 12.3% | 48.5% | 69.7% |
| Forward P/E | 0.0x | — | 24.8x | 10.1x | 9.9x |
| Total Debt | $1.29B | $22M | $70M | $956M | $15.99B |
| Cash & Equiv. | $390M | $194M | $1.12B | $43M | $924M |
CDT vs DBVT vs ALKS vs CSWC vs ARCC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 22 | May 26 | Return |
|---|---|---|---|
| CDT Equity Inc. (CDT) | 100 | 0.0 | -100.0% |
| DBV Technologies S.… (DBVT) | 100 | 125.7 | +25.7% |
| Alkermes plc (ALKS) | 100 | 134.5 | +34.5% |
| Capital Southwest C… (CSWC) | 100 | 101.1 | +1.1% |
| Ares Capital Corpor… (ARCC) | 100 | 90.5 | -9.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CDT vs DBVT vs ALKS vs CSWC vs ARCC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CDT has the current edge in this matchup, primarily because of its strength in growth and value.
- 8.9% revenue growth vs DBVT's -100.0%
- Lower P/E (0.0x vs 10.1x)
DBVT ranks third and is worth considering specifically for momentum.
- +110.4% vs CDT's -99.8%
ALKS is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
- 5.4% ROA vs DBVT's -89.0%
CSWC is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 3 yrs, beta 0.84, yield 10.2%
- 234.2% 10Y total return vs ALKS's -11.0%
- Beta 0.84, yield 10.2%
- NIM 7.0% vs ARCC's 3.6%
ARCC is the clearest fit if your priority is growth exposure.
- Rev growth 32.9%, EPS growth -23.8%
- Beta 0.77 vs CDT's 1.84
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.9% revenue growth vs DBVT's -100.0% | |
| Value | Lower P/E (0.0x vs 10.1x) | |
| Quality / Margins | 43.1% margin vs DBVT's 0.3% | |
| Stability / Safety | Beta 0.77 vs CDT's 1.84 | |
| Dividends | 10.2% yield, 3-year raise streak, vs ARCC's 2.0%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +110.4% vs CDT's -99.8% | |
| Efficiency (ROA) | 5.4% ROA vs DBVT's -89.0% |
CDT vs DBVT vs ALKS vs CSWC vs ARCC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
CDT vs DBVT vs ALKS vs CSWC vs ARCC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CSWC leads in 2 of 6 categories
ARCC leads 1 • CDT leads 1 • ALKS leads 1 • DBVT leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ARCC leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
ARCC and DBVT operate at a comparable scale, with $3.1B and $0 in trailing revenue. CSWC is the more profitable business, keeping 43.1% of every revenue dollar as net income compared to CDT's 2.4%.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $696M | $0 | $1.6B | $164M | $3.1B |
| EBITDAEarnings before interest/tax | $47M | -$112M | $212M | $142M | $2.0B |
| Net IncomeAfter-tax profit | $17M | -$168M | $153M | $103M | $1.1B |
| Free Cash FlowCash after capex | -$6M | -$151M | $392M | -$69M | $1.1B |
| Gross MarginGross profit ÷ Revenue | +36.9% | — | +65.4% | +66.5% | +75.7% |
| Operating MarginEBIT ÷ Revenue | +6.4% | — | +12.3% | +48.5% | +69.7% |
| Net MarginNet income ÷ Revenue | +2.4% | — | +9.8% | +43.1% | +41.3% |
| FCF MarginFCF ÷ Revenue | -0.9% | — | +25.1% | -132.6% | +36.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | +28.2% | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +100.4% | +91.5% | -4.1% | +113.3% | -63.9% |
Valuation Metrics
CDT leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 0.0x trailing earnings, CDT trades at a 100% valuation discount to ALKS's 24.8x P/E. On an enterprise value basis, CDT's 2.4x EV/EBITDA is more attractive than CSWC's 27.4x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $367,825 | $1712.35T | $5.9B | $1.4B | $13.6B |
| Enterprise ValueMkt cap + debt − cash | $896M | $1712.35T | $4.9B | $2.3B | $28.7B |
| Trailing P/EPrice ÷ TTM EPS | 0.00x | -0.76x | 24.76x | 16.32x | 10.19x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 10.06x | 9.92x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 0.99x |
| EV / EBITDAEnterprise value multiple | 2.43x | — | 17.25x | 27.43x | 13.09x |
| Price / SalesMarket cap ÷ Revenue | 0.00x | — | 4.00x | 8.71x | 4.33x |
| Price / BookPrice ÷ Book value/share | 0.00x | 0.66x | 3.28x | 1.39x | 0.93x |
| Price / FCFMarket cap ÷ FCF | — | — | 12.28x | — | 11.92x |
Profitability & Efficiency
ALKS leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
CSWC delivers a 10.3% return on equity — every $100 of shareholder capital generates $10 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARCC's 1.12x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs CSWC's 1/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +2.6% | -130.2% | +8.8% | +10.3% | +8.1% |
| ROA (TTM)Return on assets | +1.0% | -89.0% | +5.4% | +4.8% | +3.8% |
| ROICReturn on invested capital | +21.9% | — | +18.9% | +3.5% | +5.7% |
| ROCEReturn on capital employed | +22.2% | -145.7% | +14.2% | +4.6% | +7.5% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 | 7 | 1 | 4 |
| Debt / EquityFinancial leverage | 1.02x | 0.13x | 0.04x | 1.08x | 1.12x |
| Net DebtTotal debt minus cash | $896M | -$172M | -$1.0B | $913M | $15.1B |
| Cash & Equiv.Liquid assets | $390M | $194M | $1.1B | $43M | $924M |
| Total DebtShort + long-term debt | $1.3B | $22M | $70M | $956M | $16.0B |
| Interest CoverageEBIT ÷ Interest expense | -1.05x | -189.82x | 32.30x | 2.91x | 2.98x |
Total Returns (Dividends Reinvested)
CSWC leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,091 today (with dividends reinvested), compared to $0 for CDT. Over the past 12 months, DBVT leads with a +110.4% total return vs CDT's -99.8%. The 3-year compound annual growth rate (CAGR) favors CSWC at 20.7% vs CDT's -97.4% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -94.2% | +4.9% | +25.3% | +11.4% | -4.9% |
| 1-Year ReturnPast 12 months | -99.8% | +110.4% | +16.5% | +34.0% | +0.4% |
| 3-Year ReturnCumulative with dividends | -100.0% | +19.7% | +14.5% | +75.8% | +34.2% |
| 5-Year ReturnCumulative with dividends | -100.0% | -69.1% | +60.9% | +51.4% | +47.0% |
| 10-Year ReturnCumulative with dividends | -100.0% | -87.0% | -11.0% | +234.2% | +139.2% |
| CAGR (3Y)Annualised 3-year return | -97.4% | +6.2% | +4.6% | +20.7% | +10.3% |
Risk & Volatility
Evenly matched — CSWC and ARCC each lead in 1 of 2 comparable metrics.
Risk & Volatility
ARCC is the less volatile stock with a 0.77 beta — it tends to amplify market swings less than CDT's 1.84 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CSWC currently trades 98.2% from its 52-week high vs CDT's 0.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.84x | 1.26x | 1.06x | 0.84x | 0.77x |
| 52-Week HighHighest price in past year | $1425.00 | $26.18 | $36.60 | $24.43 | $23.42 |
| 52-Week LowLowest price in past year | $1.20 | $7.53 | $25.17 | $19.37 | $17.40 |
| % of 52W HighCurrent price vs 52-week peak | +0.1% | +76.3% | +96.7% | +98.2% | +81.0% |
| RSI (14)Momentum oscillator 0–100 | 27.2 | 48.1 | 60.2 | 63.7 | 56.7 |
| Avg Volume (50D)Average daily shares traded | 126K | 252K | 2.3M | 664K | 7.5M |
Analyst Outlook
CSWC leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: DBVT as "Buy", ALKS as "Buy", CSWC as "Buy", ARCC as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs -6.2% for CSWC (target: $23). For income investors, CSWC offers the higher dividend yield at 10.20% vs ARCC's 2.02%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $46.33 | $44.00 | $22.50 | $21.88 |
| # AnalystsCovering analysts | — | 15 | 28 | 10 | 32 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +10.2% | +2.0% |
| Dividend StreakConsecutive years of raises | 1 | 0 | 0 | 3 | 0 |
| Dividend / ShareAnnual DPS | — | — | — | $2.45 | $0.38 |
| Buyback YieldShare repurchases ÷ mkt cap | +28.8% | 0.0% | +0.5% | 0.0% | 0.0% |
CSWC leads in 2 of 6 categories (Total Returns, Analyst Outlook). ARCC leads in 1 (Income & Cash Flow). 1 tied.
CDT vs DBVT vs ALKS vs CSWC vs ARCC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CDT or DBVT or ALKS or CSWC or ARCC a better buy right now?
For growth investors, Ares Capital Corporation (ARCC) is the stronger pick with 32.
9% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). CDT Equity Inc. (CDT) offers the better valuation at 0. 0x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CDT or DBVT or ALKS or CSWC or ARCC?
On trailing P/E, CDT Equity Inc.
(CDT) is the cheapest at 0. 0x versus Alkermes plc at 24. 8x. On forward P/E, Ares Capital Corporation is actually cheaper at 9. 9x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — CDT or DBVT or ALKS or CSWC or ARCC?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.
9%, compared to -100. 0% for CDT Equity Inc. (CDT). Over 10 years, the gap is even starker: CSWC returned +234. 2% versus CDT's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CDT or DBVT or ALKS or CSWC or ARCC?
By beta (market sensitivity over 5 years), Ares Capital Corporation (ARCC) is the lower-risk stock at 0.
77β versus CDT Equity Inc. 's 1. 84β — meaning CDT is approximately 139% more volatile than ARCC relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 112% for Ares Capital Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — CDT or DBVT or ALKS or CSWC or ARCC?
By revenue growth (latest reported year), Ares Capital Corporation (ARCC) is pulling ahead at 32.
9% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: CDT Equity Inc. grew EPS 128. 8% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CDT or DBVT or ALKS or CSWC or ARCC?
Capital Southwest Corporation (CSWC) is the more profitable company, earning 43.
1% net margin versus 0. 0% for DBV Technologies S. A. — meaning it keeps 43. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARCC leads at 69. 7% versus 0. 0% for DBVT. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CDT or DBVT or ALKS or CSWC or ARCC more undervalued right now?
On forward earnings alone, Ares Capital Corporation (ARCC) trades at 9.
9x forward P/E versus 10. 1x for Capital Southwest Corporation — 0. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DBVT: 131. 8% to $46. 33.
08Which pays a better dividend — CDT or DBVT or ALKS or CSWC or ARCC?
In this comparison, CSWC (10.
2% yield), ARCC (2. 0% yield) pay a dividend. CDT, DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.
09Is CDT or DBVT or ALKS or CSWC or ARCC better for a retirement portfolio?
For long-horizon retirement investors, Capital Southwest Corporation (CSWC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
84), 10. 2% yield, +234. 2% 10Y return). CDT Equity Inc. (CDT) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CSWC: +234. 2%, CDT: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CDT and DBVT and ALKS and CSWC and ARCC?
These companies operate in different sectors (CDT (Healthcare) and DBVT (Healthcare) and ALKS (Healthcare) and CSWC (Financial Services) and ARCC (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: CDT is a small-cap deep-value stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; CSWC is a small-cap deep-value stock; ARCC is a mid-cap high-growth stock. CSWC, ARCC pay a dividend while CDT, DBVT, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.